S. Trépanier

发表

Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza

Brian J. Ward, L. Vézina, N. Landry, 2010, PloS one.

Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities

D. Vinh, Marc‐André D'Aoust, A. Makarkov, 2022, npj Vaccines.

Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults

B. Guy, B. Yassine-Diab, S. Pillet, 2019, PloS one.

A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults.

B. Yassine-Diab, S. Pillet, N. Landry, 2016, Clinical immunology.

Development and characterization of a plant-derived norovirus-like particle vaccine.

G. Andreani, Marc‐André D'Aoust, S. Pillet, 2023, Vaccine.

Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines

G. Andreani, Marc‐André D'Aoust, B. Ward, 2022, Vaccine.

Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03

L. Moulton, F. Polack, Marc‐André D'Aoust, 2022, medRxiv.

Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19

N. Landry, B. Ward, Sarah Paris-Robidas, 2021, Reproductive Toxicology.

Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.

S. Madhi, M. Couture, T. Polasek, 2021, Vaccine.

Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19

Marc‐André D'Aoust, A. Makarkov, S. Pillet, 2021, Nature Medicine.

Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants

Marc‐André D'Aoust, A. Makarkov, S. Pillet, 2020, medRxiv.

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

T. Vesikari, A. Makarkov, S. Pillet, 2020, The Lancet.

The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?

S. Pillet, N. Charland, N. Landry, 2018, Human vaccines & immunotherapeutics.

Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

B. Yassine-Diab, S. Pillet, N. Landry, 2018, npj Vaccines.

Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines.

L. Vézina, Marc‐André D'Aoust, N. Landry, 2014, Vaccine.

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.

B. Yassine-Diab, S. Pillet, N. Landry, 2014, Clinical immunology.

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.

L. Vézina, Marc‐André D'Aoust, N. Charland, 2010, Plant biotechnology journal.

Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine

L. Moulton, F. Polack, G. Pérez Marc, 2022, The New England journal of medicine.

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

Brian J Ward, S. Mongrand, L. Vézina, 2008, Plant biotechnology journal.

Characterization of the penA and penR genes of Burkholderia cepacia 249 which encode the chromosomal class A penicillinase and its LysR-type transcriptional regulator

A. Huletsky, A. Prince, S. Trépanier, 1997, Antimicrobial agents and chemotherapy.

Development and characterization of a plant-derived rotavirus-like particle vaccine.

Marc‐André D'Aoust, M. Couture, N. Tsutsui, 2021, Vaccine.

Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates

B. Pulendran, S. Boyd, G. Andreani, 2022, Cellular & molecular immunology.

Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates

B. Pulendran, S. Boyd, G. Andreani, 2021, bioRxiv.

Influenza Virus-Like Particles Produced in Nicotiana benthamiana Protect Against a Lethal Viral Challenge in Mice

L. Vézina, Marc‐André D'Aoust, N. Landry, 2014 .

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.

L. Vézina, Marc‐André D'Aoust, N. Charland, 2010, Plant biotechnology journal.

Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.

S. Mongrand, L. Vézina, Marc‐André D'Aoust, 2008, Plant biotechnology journal.

Monoclonal C5-1 antibody produced in transgenic alfalfa plants exhibits a N-glycosylation that is homogenous and suitable for glyco-engineering into human-compatible structures.

P. Lerouge, M. Bardor, L. Vézina, 2003, Plant biotechnology journal.

MsCYS1, a developmentally-regulated cystatin from alfalfa.

L. Vézina, D. Michaud, C. Girard, 2007, Plant physiology and biochemistry : PPB.

Structure-Function Studies of Ser-289 in the Class C β-Lactamase from Enterobacter cloacae P99

A. Huletsky, F. Sanschagrin, N. Clairoux, 1999, Antimicrobial Agents and Chemotherapy.

Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age.

N. Landry, B. Ward, Julie Couillard, 2021, Vaccine.

An in-built proteinase inhibitor system for the protection of recombinant proteins recovered from transgenic plants.

L. Vézina, D. Michaud, R. Anguenot, 2006, Plant biotechnology journal.

Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

B. Yassine-Diab, S. Pillet, N. Landry, 2018, npj Vaccines.

Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens.

B. Yassine-Diab, S. Pillet, N. Landry, 2014, Clinical immunology.